Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to prove the superiority of entecavir over lamivudine for preventing
the risk of hepatitis B virus reactivation in patients with non-Hodgkin lymphoma on
CHOP/R-CHOP.